BACKGROUND AND PURPOSE: During development of thoracic aortic aneurysms in a mouse model of Marfan syndrome, upregulation of matrix metalloproteinase (MMP)-2 and -9 was accompanied by compromised aortic constriction and endothelium-dependent relaxation. Losartan has been proposed for the prevention of thoracic aortic aneurysm. We hypothesized that losartan would suppress MMP-2/-9 activation and improve aortic vasomotor function in this model. EXPERIMENTAL APPROACH: A well-characterized mouse model of Marfan syndrome (Fbn1(C1039G/+)) was used. Starting at 6 weeks old, Marfan mice were untreated or given losartan (0.6 g.L(-1) in drinking water, n= 30). The littermate Fbn1(+/+) mice served as control. Thoracic aortas were studied at 3, 6 and 9 months by histology and by contractility assays in isolated segments in vitro. KEY RESULTS: Losartan improved elastic fibre organization and increased aortic breaking stress. Losartan reduced the activity and protein expression of MMP-2 and MMP-9 at all ages. Aortic constriction in response to membrane depolarization or phenylephrine was increased by losartan at 3 and 9 months by 100-200%. Active force of aortic smooth muscle was also increased at 6 and 9 months. Acetylcholine-induced endothelium-dependent relaxation was improved by 30% after 3 months of losartan treatment, but such improvement disappeared with longer duration of treatment, accompanied by reduced phosphorylation of endothelial nitric oxide (NO) synthase(Ser1177), Akt(Thr308) and Akt(Ser473), compared with the control. CONCLUSIONS AND IMPLICATIONS: Losartan improved the contractile function of aorta and reduced MMP activation. However, the endothelial NO pathway remained suppressed in the thoracic aorta during losartan treatment, which might limit its long-term benefits in Marfan syndrome.
BACKGROUND AND PURPOSE: During development of thoracic aortic aneurysms in a mouse model of Marfan syndrome, upregulation of matrix metalloproteinase (MMP)-2 and -9 was accompanied by compromised aortic constriction and endothelium-dependent relaxation. Losartan has been proposed for the prevention of thoracic aortic aneurysm. We hypothesized that losartan would suppress MMP-2/-9 activation and improve aortic vasomotor function in this model. EXPERIMENTAL APPROACH: A well-characterized mouse model of Marfan syndrome (Fbn1(C1039G/+)) was used. Starting at 6 weeks old, Marfan mice were untreated or given losartan (0.6 g.L(-1) in drinking water, n= 30). The littermate Fbn1(+/+) mice served as control. Thoracic aortas were studied at 3, 6 and 9 months by histology and by contractility assays in isolated segments in vitro. KEY RESULTS:Losartan improved elastic fibre organization and increased aortic breaking stress. Losartan reduced the activity and protein expression of MMP-2 and MMP-9 at all ages. Aortic constriction in response to membrane depolarization or phenylephrine was increased by losartan at 3 and 9 months by 100-200%. Active force of aortic smooth muscle was also increased at 6 and 9 months. Acetylcholine-induced endothelium-dependent relaxation was improved by 30% after 3 months of losartan treatment, but such improvement disappeared with longer duration of treatment, accompanied by reduced phosphorylation of endothelial nitric oxide (NO) synthase(Ser1177), Akt(Thr308) and Akt(Ser473), compared with the control. CONCLUSIONS AND IMPLICATIONS: Losartan improved the contractile function of aorta and reduced MMP activation. However, the endothelial NO pathway remained suppressed in the thoracic aorta during losartan treatment, which might limit its long-term benefits in Marfan syndrome.
Authors: Satyajit K Karnik; Benjamin S Brooke; Antonio Bayes-Genis; Lise Sorensen; Joshua D Wythe; Robert S Schwartz; Mark T Keating; Dean Y Li Journal: Development Date: 2003-01 Impact factor: 6.868
Authors: Marta Saura; Carlos Zaragoza; Wangsen Cao; Clare Bao; Manuel Rodríguez-Puyol; Diego Rodríguez-Puyol; Charles J Lowenstein Journal: Circ Res Date: 2002-11-01 Impact factor: 17.367
Authors: Enid R Neptune; Pamela A Frischmeyer; Dan E Arking; Loretha Myers; Tracie E Bunton; Barbara Gayraud; Francesco Ramirez; Lynn Y Sakai; Harry C Dietz Journal: Nat Genet Date: 2003-02-24 Impact factor: 38.330
Authors: Daniel P Judge; Nancy J Biery; Douglas R Keene; Jessica Geubtner; Loretha Myers; David L Huso; Lynn Y Sakai; Harry C Dietz Journal: J Clin Invest Date: 2004-07 Impact factor: 14.808
Authors: Siddharth Prakash; Scott A LeMaire; Molly Bray; Dianna M Milewicz; John W Belmont Journal: Am J Med Genet A Date: 2010-09 Impact factor: 2.802
Authors: Jeff Z Chen; Hisashi Sawada; Dien Ye; Yuriko Katsumata; Masayoshi Kukida; Satoko Ohno-Urabe; Jessica J Moorleghen; Michael K Franklin; Deborah A Howatt; Mary B Sheppard; Adam E Mullick; Hong S Lu; Alan Daugherty Journal: Arterioscler Thromb Vasc Biol Date: 2021-08-19 Impact factor: 10.514
Authors: Els Moltzer; Luuk te Riet; Sigrid M A Swagemakers; Paula M van Heijningen; Marcel Vermeij; Richard van Veghel; Angelique M Bouhuizen; Joep H M van Esch; Stephanie Lankhorst; Natasja W M Ramnath; Monique C de Waard; Dirk J Duncker; Peter J van der Spek; Ellen V Rouwet; A H Jan Danser; Jeroen Essers Journal: PLoS One Date: 2011-08-09 Impact factor: 3.240
Authors: James W Wisler; Emily M Harris; Michael Raisch; Lan Mao; Jihee Kim; Howard A Rockman; Robert J Lefkowitz Journal: Am J Physiol Heart Circ Physiol Date: 2015-09-14 Impact factor: 4.733
Authors: Christine H Attenhofer Jost; Matthias Greutmann; Heidi M Connolly; Roland Weber; Marianne Rohrbach; Angela Oxenius; Oliver Kretschmar; Thomas F Luscher; Gabor Matyas Journal: Curr Cardiol Rev Date: 2014-05